Many breast cancer patients develop resistance to standard drug treatments aimed at preventing the growth of cancer cells. A team from the University of Geneva (UNIGE) has identified a molecular regulator involved in these resistance mechanisms.
The loss of this regulator leads to the proliferation of cancer cells - even if they are treated - through a signalling pathway that can itself be inhibited by another treatment.
The team’s findings make it possible to consider dual therapy for certain patients whose tumours no longer respond to standard treatment. This work can be read in the journal Cancers.
In the majority of patients with breast cancer, one of the female hormones - oestrogen - plays a harmful role. In about two-thirds of breast cancers, the tumors contain a receptor for this hormone, which is produced by the ovaries.
When oestrogen binds to its receptor, it stimulates the growth of cancer cells. To treat these forms of tumours sensitive to hormones, it is possible to use hormone therapy, which consists of a drug treatment to prevent the cancer cells’ stimulation by the female hormone.
More than a third of patients become resistant to treatment
The standard molecule used in the treatment of hormone-sensitive breast cancer is tamoxifen. This molecule, which binds to oestrogen receptors to block them, prevents oestrogen binding and thus the stimulation of cancer cell growth. However, in about 40% of treated patients, the cancer cells eventually develop resistance to this molecule.
The laboratory of Professor Didier Picard of the Department of Molecular and Cellular Biology of the Faculty of Science of the UNIGE is interested in the molecular mechanisms responsible for these resistance phenomena. The biologists used a genetic approach on cancer cell lines to look for factors that promote the development of tamoxifen resistance.
“We used the CRISPR/Cas9 molecular scissors technique to generate cells in which a different gene was removed each time. We then observed the cancer cells able to proliferate even in the presence of tamoxifen,” explains Vasiliki Vafeiadou, a master’s student in the Department of Molecular and Cellular Biology and first author of the study. Thus, the scientists identified that low levels of the SPRED2 protein cause cancer cells to become resistant to treatment.
Combining drugs for better treatment
When present in sufficient quantities, this protein prevents cell growth by blocking a signalling pathway that activates cell proliferation. When it is absent - or present in low amounts - then cell growth is activated, even in the presence of tamoxifen, which prevents oestrogen-dependent stimulation.
“By analysing databases listing the expression levels of certain genes in patients, we were able to see that those with low levels of SPRED2 have a poorer prognosis,” says Dina Hany, a researcher in the Department of Molecular and Cellular Biology and co-lead author of the study.
A treatment capable of inhibiting this oestrogen-independent cell activation pathway is already in clinical trials. The authors, therefore, propose to combine tamoxifen with this other molecule in patients with low levels of SPRED2. “There are obviously still many studies to be conducted, but this combination of treatments could be very promising,” concludes Didier Picard.
Source: Université de Genève
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.